New Drugs and Clinical Research · global
RAS inhibitor extends survival in advanced pancreatic cancer; mRNA flu vaccine and oral dermatomyositis drug receive U.S. approval
In August 2026, the United States approved several new therapies in succession. Among them, daraxonrasib increased median overall survival to 13.2 months in patients with metastatic pancreatic cancer in a randomized trial. Each new option across these different diseases also comes with evidence limitations that require careful consideration.
For patients with metastatic pancreatic cancer whose disease continues to progress despite prior treatment, extending life is the most direct measure of a new drug. On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved the RAS inhibitor daraxonrasib under the brand name RASONQUE. The randomized trial supporting approval showed median overall survival of 13.2 months in the treatment group versus 6.7 months in the standard chemotherapy group, offering a new option for patients with limited treatment choices.
Daraxonrasib targets the RAS family of proteins involved in cell growth signaling. It is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are not suitable for multiagent systemic therapy. The RASolute 302 trial enrolled 500 patients whose disease had progressed after first-line systemic therapy and randomly assigned them to daraxonrasib or standard chemotherapy selected by their physician. In addition to the improvement in overall survival, median progression-free survival was 7.2 and 3.6 months in the two groups, respectively.
This difference reflects results in the trial population and cannot be interpreted to mean that every patient will live the same amount of additional time. The study used an open-label design, and the main evidence came from patients whose prior treatment had failed; an equivalent benefit cannot be directly inferred for first-line treatment. The drug's safety warnings also cover serious risks, including gastrointestinal perforation and interstitial lung disease or pneumonitis. The convenience of oral administration does not eliminate the need for monitoring during treatment.
The same month also brought a platform change in preventive medicine. On August 5, the FDA approved ModernaTX's mRNA influenza vaccine MFLUSIVA for adults aged 50 and older to prevent influenza caused by the influenza A and B strains covered by the vaccine. A drug review by 2 Minute Medicine noted that this is the first approved mRNA influenza vaccine. However, the FDA prescribing information clearly distinguishes the evidence: the indication for adults aged 65 and older received accelerated approval based on immune responses, and confirmatory trials are still required to verify clinical benefit. Reactions such as injection-site pain, fatigue, and muscle aches were also more common than with the standard-dose comparator vaccine.
Another advance concerned a rare autoimmune disease that damages muscles and skin. On August 27, the FDA announced the approval of Lisraya (brepocitinib), making it the first FDA-approved oral treatment specifically indicated for adults with dermatomyositis. This JAK/TYK2 inhibitor works by blocking inflammatory signaling. The phase 3 double-blind trial supporting approval enrolled 241 adults and compared daily doses of 30 mg and 15 mg with placebo over 52 weeks.
The approved 30 mg dose produced a higher Total Improvement Score at week 52, along with improvements in physical function and skin disease activity, and patients were more likely to reduce their steroid use at week 48. However, the FDA announcement did not report the full magnitude of benefit on the primary score, so the approval announcement alone cannot establish how much an individual patient might improve. Lisraya also carries a boxed warning covering serious infections, mortality, malignancies, major adverse cardiovascular events, and thrombosis. Efficacy and risks must be weighed together.
Ecopipam, the Tourette syndrome drug mentioned in the same review, remained under review. According to 2 Minute Medicine, the FDA accepted its marketing application for a pediatric indication on August 19 and granted priority review. In a phase 3 randomized withdrawal trial, this selective dopamine D1 receptor antagonist reduced relapse among pediatric patients who had previously responded and continued taking the drug. This design primarily addresses whether efficacy can be maintained and cannot directly represent the effects in all children starting treatment for the first time. Acceptance of an application is also distinct from formal approval, and long-term tolerability remains part of further evaluation.